The stock of VolitionRX Ltd (NYSEMKT:VNRX) is a huge mover today! The stock increased 4.37% or $0.19 on November 23, hitting $4.54. About 66,760 shares traded hands or 25.87% up from the average. VolitionRX Ltd (NYSEMKT:VNRX) has risen 29.71% since April 22, 2016 and is uptrending. It has outperformed by 24.30% the S&P500.
The move comes after 6 months positive chart setup for the $115.03 million company. It was reported on Nov, 24 by Barchart.com. We have $4.95 PT which if reached, will make NYSEMKT:VNRX worth $10.35M more.
Analysts await VolitionRX Ltd (NYSEMKT:VNRX) to report earnings on March, 10. They expect $-0.14 earnings per share, up 6.67% or $0.01 from last year’s $-0.15 per share. After $-0.15 actual earnings per share reported by VolitionRX Ltd for the previous quarter, Wall Street now forecasts -6.67% EPS growth.
According to Zacks Investment Research, “Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer types. The Company’s development activities are primarily centered in Belgium. Volition RX Ltd is based in Singapore.”
Insitutional Activity: The institutional sentiment decreased to 1.8 in Q2 2016. Its down 1.70, from 3.5 in 2016Q1. The ratio worsened, as 1 funds sold all VolitionRX Ltd shares owned while 1 reduced positions. 2 funds bought stakes while 5 increased positions. They now own 6.13 million shares or 0.84% more from 6.08 million shares in 2016Q1.
Morgan Stanley, a New York-based fund reported 51,900 shares. The New York-based Lagoda Investment Mgmt Lp has invested 1.9% in VolitionRX Ltd (NYSEMKT:VNRX). Asset Mgmt Inc has invested 0.01% of its portfolio in VolitionRX Ltd (NYSEMKT:VNRX). Garrison Bradford Associate has 15,500 shares for 0.05% of their US portfolio. Retail Bank Of America Corporation De has invested 0% of its portfolio in VolitionRX Ltd (NYSEMKT:VNRX). Southpoint Advisors Lp accumulated 800,000 shares or 0.13% of the stock. Blackrock, a New York-based fund reported 1,000 shares. National Bank Of New York Mellon Corp last reported 10,355 shares in the company. Goldman Sachs Group holds 19,388 shares or 0% of its portfolio. Knoll Cap Management Ltd Partnership holds 461,538 shares or 0.47% of its portfolio. Blackrock Fund last reported 2,349 shares in the company. Moreover, Tower Capital Limited Liability Com (Trc) has 0% invested in VolitionRX Ltd (NYSEMKT:VNRX) for 659 shares. Blackrock Advsr Ltd Liability Co accumulated 1,424 shares or 0% of the stock. Moreover, Creative Planning has 0% invested in VolitionRX Ltd (NYSEMKT:VNRX) for 3,200 shares. Geode Mngmt Lc accumulated 0% or 63,662 shares.
Insider Transactions: Since October 5, 2016, the stock had 1 insider purchase, and 0 sales for $50,000 net activity. The insider KRATOCHVIL DAVID MATTHEW bought 10,000 shares worth $50,000.
More notable recent VolitionRX Ltd (NYSEMKT:VNRX) news were published by: Marketwatch.com which released: “VolitionRX Ltd. NYSE MKT: VNRX” on October 31, 2011, also Prnewswire.com with their article: “VolitionRx Limited to Present at the Canaccord Genuity Medical Technologies …” published on November 11, 2016, Quotes.Wsj.com published: “VolitionRX Ltd. VNRX (US: NYSE MKT)” on May 24, 2014. More interesting news about VolitionRX Ltd (NYSEMKT:VNRX) were released by: Prnewswire.com and their article: “VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriter” published on October 21, 2016 as well as Prnewswire.com‘s news article titled: “VolitionRx Limited Schedules Third Quarter 2016 Earnings Conference Call and …” with publication date: November 04, 2016.
VNRX Company Profile
VolitionRx Limited, incorporated on September 24, 1998, is a clinical-stage life sciences company. The Firm is focused on developing blood diagnostic tests for detecting and diagnosing cancer and other diseases. The Firm has developed approximately 30 blood assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company’s Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Firm is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company’s NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.